Haemadipsin
Anticoagulant peptide described in the terrestrial Asian leech Haemadipsa zeylanica.
Praeklinisch / mechanistischLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Anticoagulant peptide described in the terrestrial Asian leech Haemadipsa zeylanica.
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Haemadipsin is documented mechanistically only; no human evidence. No FDA-approved derivative exists and whole-leech application of Haemadipsa is not an approved therapy.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 6,500 Da
- Source species
- Haemadipsa zeylanica
- Discovered
- 2016
Biological Targets
- → thrombin (Factor IIa)
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.